HCM Hutchison MediPharma: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

hutch-med.com (HCM) - corporate logo

Can HUTCHMED (China) Limited (HCM) successfully scale its developments abroad through licensing agreements? The answer lies in the creation of targeted oncology drugs and partnerships with tech giants, which generate free cash flow. The EV/EBITDA multiple dynamics for this heavy business confirm the efficiency of production capacities in the PRC, while the 0.00 indicator determines the status of the asset's fundamental value parameter.

HUTCHMED Ltd - HCM Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/14/2026)

hutch-med.com (HCM) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart HUTCHMED Ltd|HCM - Average Forecast Price
- company stock capitalization data:
Market Value HUTCHMED Corp|HCM - Business Value
- book value of equity indicators:
Book Value per Share HUTCHMED|HCM - Company Net Assets|Market Value to Book Value Ratio hutch-med.com|HCM - Company Assets
- company total debt and liquidity indicators:
Debt to Equity HUTCHMED (China) Limited|HCM - Long-Term Debt to Equity|Short-Term Debt to Equity HUTCHMED|HCM - Company Cumulative Debt|Debts to Book Capitalization HUTCHMED Corp|HCM - Long-Term Indebtedness|Company Current Liabilities HUTCHMED|Quick Liquidity Indicator hutch-med.com
- financial results and valuation multiples details:
HCM - Final Profit|Future Profit HUTCHMED (China) Limited|HCM - Market Price to Net Income Ratio|Forward P/E Multiple HUTCHMED (China) Limited|HCM - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple HUTCHMED Corp|HCM - Profit before interest, taxes and amortization|Earnings per share for the last twelve months HUTCHMED|HCM - Earnings per share for the trailing year|Quarterly EPS earnings growth hutch-med.com|HCM - Earnings growth in current year|Net earnings per share growth forecast for next year HUTCHMED (China) Limited
- sales and revenue data:
HCM - Company Annual Revenue|Company Future Sales Volume HUTCHMED Ltd|HCM - Price to Sales|Forward P/S Multiple HUTCHMED Corp
Initial company analysis:HUTCHMED Ltd HCM
Original product of HUTCHMED

To find fundamental support in the capital-intensive business of HUTCHMED (HCM), which is building a global oncology therapy ecosystem, analyzing enterprise value relative to operating income is critical. By tracking changes in the EV/EBITDA multiple, an investor assesses the efficiency of profit generation before interest and taxes, allowing them to distinguish genuine asset undervaluation from a risky "value trap" during periods of market volatility.

Main competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Incyte Corp. INCY|Nuvation Corp (NUVB) - Company Value to EBITDA|DAWN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MNPR (monopartx.com) - Enterprise Value to Operating Income Before Depreciation|INBX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio I-Mab Biopharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Fennec Pharmaceuticals Inc|Company Value to EBITDA Heron Therapeutics Inc HRTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nuvectis Pharma, Inc. (NVCT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CHRS (Coherus BioSciences, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Corbus Pharmaceuticals Holdings CRBP|Cardiff Oncology Inc. (CRDF) - Company Value to EBITDA|BeyondSpring Pharma - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple BioAtla, Inc. (BCAB)|LIXT (Lixte Biotechnology) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Citius Pharmaceuticals, Inc. (CTXR)|Enterprise Value to EBITDA Ratio CLRB|BLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|Enterprise Value to Operating Income Before Depreciation Ratio APRE|EV/EBITDA Multiple KZIA (Kazia Therapeutics Limited)|Business Value to Operating Income Before Depreciation SLXN|NuCana Corp - EV/EBITDA Multiple|Company Value to EBITDA Chimerix Inc.|Cyclacel Pharmaceuticals Inc. (CYCC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|G1 Therapeutics - Business Value to Operating Income Before Depreciation|KRON (Kronos Bio, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple kintara.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oncternal Therapeutics, Inc. (ONCT)|PRTG: Company Value to Operating Income Before Depreciation Ratio